Fibroblast-Mediated Resistance to BRAF Inhibition in Metastatic Melanoma - Effect of drugs targeting PI3K/AKT/mTOR signaling pathway
Year: 2018
Type: dissertation
Abstract: Introduction.Metastatic melanoma is an aggressive type of skin cancer for which the incidence rate has dramatically increased worldwide, especially in the Scandinavian countries.Targeted therapy with the BRAF inhibitor vemurafenib (BRAFi) has significantly improved clinical responses in melanoma patients carrying the BRAF V600 mutation.However, the clinical benefit is limited due to development of resistance.Recently, our group demonstrated that the presence of stromal cells, such as fibroblasts, can significantly influence mela noma sensitivity to BRAFi, indicating fibroblast-mediated protection from the drug.In this master project we investigated whether using a combination of BRAFi and drugs targeting PI3K/AKT/mTOR pathway could eliminate the fibroblast-mediated protection.Methods.The drug sensitivity in two metastatic melanoma cell lines, HM8 and Melmet 5, was evaluated at different doses of selected inhibitors (BRAFi, CK2i, PI3Ki or mTORi).All inhibitors were used alone or with BRAFi combined with CK2i, PI3Ki or mTORi.First, the treatment effects on cell viability/proliferation were tested in melanoma mono-cultures.Subsequently melanoma cells were co-cultured with the fibroblast cell line WI-38, and treated with BRAFi alone or in combination with CK2i, PI3Ki or mTORi.Three different techniques, Western immunoblotting, Simple Western immunoassay and flow cytometry were used to investigate the levels of the phospho-proteins, pERK and pS6, reflecting the activity of the MAPK/ERK and PI3K/AKT/mTOR signaling pathways.Results.The mono-cultured HM8 and Melmet 5 cells showed decreased cell viability with increasing concentrations of the mono-treatments.In addition, the BRAFi in combination with CK2i, PI3Ki or mTORi also reduced the melanoma cells' viability in mono-cultures.However, this reduction was mostly induced by the BRAFi.When HM8 co-cultures were treated with BRAFi, a lower sensitivity to this inhibitor was observed, indicating the fibroblast-mediated protection.The fibroblast-mediated protection was reduced or eliminated in co-cultures when the combination treatments of BRAFi with CK2i, PI3Ki or mTORi were used.Finally, the protein analysis revealed that BRAFi strongly reduced pERK and pS6 protein levels in the mono-cultures, and no additional effect was observed when BRAFi was combined with CK2i.In contrast, in the co-cultures, the effect of BRAFi on pERK and pS6 was lower and the combination treatment of BRAFi and CK2i further reduced the levels of these phospho-proteins.VI Conclusions.The presence of fibroblasts protected melanoma cells from BRAFi.Combination treatment of BRAFi with drugs targeting PI3K/AKT/mTOR pathway, reduced/eliminated fibroblast-mediated protection.In the co-cultures, the BRAFi in combination with CK2i suppressed the MAPK/ERK and PI3K/AKT/mTOR signaling pathways more efficiently than BRAFi mono-treatment.In the mono-cultures, however, treatment with BRAFi was effective in suppressing both signaling pathways and the combination treatment with both inhibitors did not add any additional effec t in suppression.This data suggest that combining BRAFi with PI3K/AKT/mTOR pathway inhibitors might overcome fibroblast-mediated protection and might be an attractive alternative for treating stroma-rich melanoma tumors.
Source: NVA (Nasjonalt vitenarkiv)
Author: Marta Gawraczynska
Institution: University of Oslo
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2943395261
